In this study, we demonstrated that concurrent inhibition of STAT3, SRC, PI3/AKT/mTOR, and MAPK pathways most effectively improved the anti-tumor activity of paclitaxel both in vitro and in vivo, providing a potential therapeutic strategy to improve clinical benefit of paclitaxel in ovarian cancer patients. Here, SRC is linked to ovarian carcinoma.